The DOI matches its Crossref record; 228 of the 230 references it cites were found in a registry or an index.
Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes
Open accessAbstract
Post-transplant diabetes mellitus (PTDM) is a frequent consequence of solid organ transplantation. PTDM has been associated with greater mortality and increased infections in different transplant groups using different diagnostic criteria. An international consensus panel recommended a consistent set of guidelines in 2003 based on American Diabetes Association glucose criteria but did not exclude the immediate post-transplant hospitalization when many patients receive large doses of corticosteroids. Greater glucose monitoring during all hospitalizations has revealed significant glucose intolerance in the majority of recipients immediately after transplant. As a result, the international consensus panel reviewed its earlier guidelines and recommended delaying screening and diagnosis of PTDM until the recipient is on stable doses of immunosuppression after discharge from initial transplant hospitalization. The group cautioned that whereas hemoglobin A1C has been adopted as a diagnostic criterion by many, it is not reliable as the sole diabetes screening method during the first year after transplant. Risk factors for PTDM include many of the immunosuppressant medications themselves as well as those for type 2 diabetes. The provider managing diabetes and associated dyslipidemia and hypertension after transplant must be careful of the greater risk for drug-drug interactions and infections with immunosuppressant medications. Treatment goals and therapies must consider the greater risk for fluctuating and reduced kidney function, which can cause hypoglycemia. Research is actively focused on strategies to prevent PTDM, but until strategies are found, it is imperative that immunosuppression regimens are chosen based on their evidence to prolong graft survival, not to avoid PTDM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The clinical importance of PTDM lies in its unquestionable impact as a signi fi cant risk factor for cardiovascular disease and chronic kidney disease in solid-organ transplantation (137).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [137]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The clinical importance of PTDM lies in its impact as a significant risk factor for cardiovascular disease and chronic kidney disease in solid-organ transplantation (137).”
From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [137]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Inflammation and metabolic disorders
Hotamisligil, G. S. (2006) · Nature · doi:10.1038/nature05485 · Cited by 9,199
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
Kim, D.-H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 2,986
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Classification and Diagnosis of Diabetes
Fajans, S. S. (1990) · Medical Entomology and Zoology · Cited by 2,359
Cited by
Items 101–200 of 328
Sridhar, V. S., Ambinathan, J. P. N., Gillard, P., Mathieu, C., Cherney, D. Z. I., Lytvyn, Y., & Singh, S. K. (2021) · Transplantation · doi:10.1097/tp.0000000000003919 · Cited by 15
Cheng, F., Li, Q., Wang, J., Wang, Z., Zeng, F., & Zhang, Y. (2022) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2022.05.013 · Cited by 15
Mota-Zamorano, S., Luna, E., García‐Pino, G., González, L. M., & Gervasini, G. (2019) · Annals of Medicine · doi:10.1080/07853890.2019.1614656 · Cited by 14
Tao, Z., Luo, Z., Zou, Z., Ye, W., Hao, Y., Li, X., Zheng, K., Wu, J., Xia, J., Zhao, Y., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1580369 · Cited by 14
Posttransplant complications: molecular mechanisms and therapeutic interventions
Liu, X., Shen, J., Yan, H., Hu, J., Liao, G., Ding, L., Zhou, S., Zhang, J., Liao, J., Guo, Z., et al. (2024) · MedComm · doi:10.1002/mco2.669 · Cited by 19
“7 246 Among these, metformin has many advantages as a potential first-line agent for posttransplant PTDM. 247 Shivaswamy et al. 248 demonstrated that in rats, metformin tended to reduce tacrolimus/sirolimus treatment-induced endocrine cell apoptosis and ameliorate hyperglycemia induced by these…”
BackgroundKunasol, C., Chattipakorn, N., & Chattipakorn, S. C. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177176 · Cited by 14
Diker‐Cohen, T., Polansky, A., Bergman, I., Ayada, G., Babich, T., Akirov, A., Steinmetz, T., & Dotan, I. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101627 · Cited by 14
Chanchlani, R., Kim, S. J., Dixon, S. N., Jassal, V., Banh, T. H. M., Borges, K., Vasilevska-Ristovska, J. Z., Paterson, J. M., Ng, V. L., Dipchand, A. I., et al. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy213 · Cited by 14
Malyala, R., Rapi, L., Nash, M. M., & Prasad, G. V. R. (2019) · Canadian Journal of Kidney Health and Disease · doi:10.1177/2054358119850536 · Cited by 14
pre-existing diabetes and PTDM in kidney transplant recipients: how to handle immunosuppression
Chevallier, E., Jouvé, T., Rostaing, L. P. E., Malvezzi, P., & Noble, J. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1851596 · Cited by 16
Lo, C., Toyama, T., Oshima, M., Jun, M., Chin, K. L., Hawley, C. M., & Zoungas, S. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009966.pub3 · Cited by 30
Abazari, M. F., Karizi, S. Z., Hajati‐Birgani, N., Norouzi, S., Khazeni, Z., Hashemi, J., Shafaghi, L., Soleimanifar, F., Mansour, R. N., & Enderami, S. E. (2020) · Gene · doi:10.1016/j.gene.2020.145333 · Cited by 13
Cheng, C.-Y., Feng, Y., & Wang, H. (2020) · Korean Journal of Transplantation · doi:10.4285/kjt.20.0026 · Cited by 13
“PTDM is not only associated with increased mortality and morbidity, but also with higher rates of cardiovascular diseases and infection, which severely affect longterm graft survival and cause patient death [3-5].”
BackgroundConstantinescu, A. A., Abbas, M., Kassem, M., Gleizes, C., Kreutter, G., Schini‐Kerth, V. B., Mitrea, I. L., Toti, F., & Kessler, L. (2016) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-016-2736-8 · Cited by 15
Zhang, X., Men, T., Liu, H., Li, X., Wang, J., & Lv, J. (2018) · Transplant Immunology · doi:10.1016/j.trim.2018.04.001 · Cited by 14
Ni, Q., Song, J., Wang, Y., Sun, J., Xie, J., Zhang, J., Ning, G., Wang, W., & Wang, Q. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa786 · Cited by 13
Lawendy, B., Srinathan, S., Kotha, S., Gomes, C., Misra, S., Yu, J., Orchanian‐Cheff, A., TOMLINSON, G. A., & Bhat, M. (2021) · Clinical Transplantation · doi:10.1111/ctr.14340 · Cited by 19
van Wilpe, R., Hulst, A. H., Siegelaar, S. E., DeVries, J. H., Preckel, B., & Hermanides, J. (2022) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2022.111012 · Cited by 16
Kang, E., Lee, J., Kang, D. H., Park, J., Park, S., Kim, Y. C., Kim, D. K., Joo, K. W., Kim, Y. S., Park, M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-25070-z · Cited by 13
Post-transplantation diabetes mellitus in pediatric patients
Grundman, J. B., Wolfsdorf, J. I., & Marks, B. E. (2020) · Hormone Research in Paediatrics · doi:10.1159/000514988 · Cited by 12
Diabetic Kidney Disease in Post-Transplant Diabetes Mellitus: Causes, Treatment and Outcomes
Lim, L., Chang, J., & Kuo, H. (2023) · Biomedicines · doi:10.3390/biomedicines11020470 · Cited by 12
“CMV infection may lead to the destruction of pancreatic β-cells or the production of pro-inflammatory cytokines, but further studies are required to investigate these mechanisms [21].”
BackgroundTiwari, D., & Aw, T. C. (2024) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2024.00013 · Cited by 19
Miyazaki, R., & Miyagi, K. (2022) · BMC Nephrology · doi:10.1186/s12882-022-02793-9 · Cited by 15
“For this reason, there is little literature on the use of SGLT2 inhibitors for PTDM, and they are rarely used [6].”
BackgroundEndocrine complications after solid-organ transplant in cystic fibrosis
Sidhaye, A. R., Goldswieg, B., Kaminski, B. A., Blackman, S. M., & Kelly, A. T. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.08.019 · Cited by 16
Tantisattamo, E., & Kalantar‐Zadeh, K. (2020) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000677 · Cited by 14
“Posttransplant diabetes mellitus (PTDM) worsens short- and long-term poor kidney allograft and patient outcomes [35]; however, strong evidence related to the use of antihyperglycemic agents in kidney transplant population is lacking.”
BackgroundThiruvengadam, S., Hutchison, B., Lim, W., Bennett, K., Daniels, G., Cusack, N., Jacques, A., Cawley, B., Thiruvengadam, S., & Chakera, A. (2019) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2019.04.020 · Cited by 11
Lee, L. M., Zhang, H., Lee, K., Liang, H. K., Merleev, A. A., Vincenti, F. G., Maverakis, E., Thomson, A. W., & Tang, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.679675 · Cited by 12
“For example, corticosteroids are toxic to pancreatic islets and can cause post-transplant diabetes (3).”
BackgroundSenior, P. A., Almehthel, M. S., Miller, A., & Paty, B. W. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.017 · Cited by 12
Falasinnu, T., O'Shaughnessy, M. M., Troxell, M. L., Charu, V., Weisman, M. H., & Simard, J. F. (2019) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2019.10.006 · Cited by 11
Osté, M. C. J., Flores-Guerrero, J. L., Gruppen, E. G., Kieneker, L. M., Connelly, M. A., Otvos, J. D., Dullaart, R. P. F., & Bakker, S. J. L. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020511 · Cited by 11
“The clinical significance or impact of the diagnosis of PTDM early or late after transplantation has yet to be determined [16].”
BackgroundDu, Q., Li, T., Yi, X., Song, S., Kang, J. F., & Jiang, Y. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02253-w · Cited by 13
“Studies have demonstrated that FK506 exerts a direct toxic effect on pancreatic beta cells, resulting in cytoplasmic swelling, induction of cell apoptosis, and ultimately leading to reduced insulin synthesis and secretion [104, 110].”
InfluentialUse of glucagon-like peptide type 1 receptor agonists in kidney transplant recipients
Vigara, L. A., Villanego, F., Orellana, C., Eady, M., Sánchez, M. G., Alonso, M., García, M. B., Amaro, J. M., García, T. G., & Mazuecos, A. (2024) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2024.11.007 · Cited by 12
Implementing a pharmacist-led transition of care model for posttransplant hyperglycemia
Do, V., Haakinson, D. J., Belfort‐DeAguiar, R., & Cohen, E. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxab151 · Cited by 11
“For maintenance immunosuppression, tacrolimus has various metabolic effects that predispose patients to diabetes, including reducing insulin secretion due to the destruction of pancreatic β-cell mass and increased islet apoptosis.(6) Patients also undergo physiologic”
BackgroundPost-Transplant Diabetes: Prevalence, Risk, and Management Challenges
Bashier, A. M., Kumar, D., Alalawi, F. J. A., Alnour, H. H., Alhadari, A. K., & Hussain, A. A. B. (2022) · Dubai Diabetes and Endocrinology Journal · doi:10.1159/000522092 · Cited by 11
Nie, H.-B., Wang, W., Zhao, Y., Zhang, X., Xiao, Y., Zeng, Q., Zhang, C., & Zhang, L. (2019) · Annals of Transplantation · doi:10.12659/aot.909099 · Cited by 9
“Post-transplantation DM occurs frequently after solid organ transplantation and is associated with increased risk of opportunistic infection and higher mortality rates [2].”
BackgroundComparison of Glucose Tolerance between Kidney Transplant Recipients and Healthy Controls
Shimada, H., Uchida, J., Nishide, S., Kabei, K., Kosoku, A., Maeda, K., Iwai, T., Naganuma, T., Takemoto, Y., & Nakatani, T. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8070920 · Cited by 10
Salivary Biomarkers and Oral Health in Liver Transplant Recipients, with an Emphasis on Diabetes
Norrman, A. E., Tervahartiala, T. I., Sahlberg, E., Sorsa, T. A., Ruokonen, H., Grönroos, L., Meurman, J. H., Isoniemi, H., Nordin, A. J., Åberg, F. O., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11040662 · Cited by 10
“The life-long immunosuppressive medication taken by LT recipients exposes them, for example, to cardiovascular complications, metabolic syndrome, and diabetes [35,36].”
BackgroundBülbüloğlu, S., & Kapıkıran, G. (2021) · Transplant Immunology · doi:10.1016/j.trim.2021.101470 · Cited by 9
“It has also been proven that its use with tacrolimus and cyclosporine enhances the overall diabetogenic effect [30].”
Cheng, F., Li, Q., Wang, J., Wang, Z., Zeng, F., & Zhang, Y. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s356543 · Cited by 11
“Moreover, patients with diabetes mellitus may be at higher risk of infection-related mortality than the general population.(52,53) Therefore, regular monitoring of the kidney function of patients who have experienced infection is essential to prevent adverse clinical events.”
BackgroundStruja, T., Nitritz, N., Alexander, I., Kupferschmid, K., Hafner, J. F., Spagnuolo, C., Schüetz, P., Müeller, B., & Blum, C. A. (2024) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-023-00158-1 · Cited by 12
“We excluded RCTs on solid organ transplant patients only, as the main immunosuppressive agents have a potentially diabetogenic effect, which differs from the GC effect [14].”
BackgroundSimonenko, M., Hansen, D., Niebauer, J., Volterrani, M., Adamopoulos, S. N., Amarelli, C., Ambrosetti, M., Anker, S. D., Bayés‐Genís, A., Gal, T. B., et al. (2024) · Transplant International · doi:10.3389/ti.2024.13191 · Cited by 9
“However, there are reports that both glucose intolerance and dyslipidaemia, that occur predominantly with mTOR inhibitors, improve as the drug dose is reduced [54].”
BackgroundBacteriophages targeting Acinetobacter baumannii in the era of antibiotic failure: a review
Fortaleza, J. A. G., Cabuhat, K. S. P., Kim, S., Mortel, F. A., Bacalzo, G. D., & Nuevo, J. J. M. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1778984 · Cited by 9
“…interventions against multidrug-resistant A. baumannii , with studies consistently reporting favorable safety profiles, reductions in bacterial burden, improved clinical recovery, and enhanced efficacy when phages are combined with antibiotics (Shivaswamy et al., 2016; Kusradze et al., 2016).”
Alfieri, C., Campioli, E., Fiorina, P., Orsi, E., Grancini, V., Regalia, A. L., Campise, M., Verdesca, S., Delfrate, N. W., Molinari, P., et al. (2024) · Nutrients · doi:10.3390/nu16101520 · Cited by 8
“Numerous studies identify them as relevant causes of high cardiovascular mortality [1–3].”
BackgroundTuttle, K. R., & McGill, J. B. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13986 · Cited by 8
“Target HbA1c levels are also uncertain for patients with diabetes on chronic dialysis or with a kidney transplant, and will depend on age, comorbidities and the risk of hypoglycaemia.(19,20) Therefore, the approach to glycaemic management in patients with T2D and advanced CKD should be individualized, taking account o…”
BackgroundChisholm‐Burns, M. A., Spivey, C. A., Tsang, C. C. S., & Wang, J. (2022) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2022.28.6.688 · Cited by 8
Kong, D. C. C., Akbari, A., Malcolm, J., Doyle, M.-A., & Hoar, S. (2020) · Canadian Journal of Kidney Health and Disease · doi:10.1177/2054358120922628 · Cited by 8
Effect of histone deacetylase inhibitor (vorinostat) on new-onset diabetes induced by tacrolimus
Bakhdar, F. A., Kawy, H. S. A., Magadmi, R. M., Elkordy, E. A., & Alamri, A. S. (2022) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2022.07.004 · Cited by 7
“Subsequently, hyperglycemia increases oxidative stress, which in turn produces further b-cell apoptosis.7 This cycle leads to the development of NODAT.8 NODAT can generate serious complications that affect many organs,9 and potentially lead to the failure or rejection of transplanted kidneys.8 Although classical hypog…”
BackgroundInfluentialAleksić, S., Eisenberg, R. E., Tsomos, E., Anaraki, S. Z., Japp, E., Upadhyay, L., Mowrey, W. B., Akalin, E., & Zonszein, J. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108221 · Cited by 7
Medical care of liver transplant patients
Hoppmann, N. A., & Massoud, O. I. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1797483 · Cited by 10
“TAC has a minor effect on lipids, but CsA has been shown to increase LDL and total cholesterol to a greater extent [114,134].”
BackgroundInfluentialJob, K. M., Roberts, J. K., Enioutina, E. Y., Illamola, S. M., Kumar, S. S., Rashid, J., Ward, R. M., Fukuda, T., Sherbotie, J. R., & Sherwin, C. M. T. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1943356 · Cited by 7
“corticosteroids, raises the risk of morbidity and mortality [94,95].”
BackgroundGlucose tolerance in a cohort of Egyptian children after kidney transplantation
Arafa, N., Bazaraa, H. M., eldin, H. S., Hussein, M., & Salah, D. M. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108605 · Cited by 7
Paccagnella, C., Andreola, S., Gambaro, A., Gambaro, G., & Caletti, C. (2025) · Cardiorenal Medicine · doi:10.1159/000542378 · Cited by 7
“Inhibitors of mTOR can also result in a diabetic condition by reducing beta-pancreatic cell proliferation and insulin sensitivity [68].”
Kukla, A., Alexander, M. P., Túrkevi-Nagy, S., Merzkani, M. A., Park, W. D., Smith, B. H., Zhang, P., Benavides, X., D’Costa, M. R., Alvarez, C., et al. (2020) · Clinical Transplantation · doi:10.1111/ctr.14147 · Cited by 6
Kuang, W., Raven, L. M., & Muir, C. A. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2307011 · Cited by 7
“The proposed pathogenesis is via pro-inflammatory cytokine production and virally induced β-cell apoptosis [51].”
BackgroundResultInfluentialImmunomodulation in post-transplant diabetes mellitus: Challenges and management
Maoz, H., & Elalouf, A. (2025) · Transplant Immunology · doi:10.1016/j.trim.2025.102304 · Cited by 9
Huang, Y., Tsou, M., Li, P., Chen, J., Liu, Y., Meyerowitz‐Katz, G., Tsai, T., & Su, P. (2025) · Advanced Science · doi:10.1002/advs.202518813 · Cited by 8
Research Progress on Th17/Treg Cell Imbalance in Epileptic Seizures
Mu, L., Rong, Y., Yang, X., Zhang, H., & Xu, Z. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s524814 · Cited by 7
“80,81 Treg cells mostly preserve grafts by modulating immune responses.”
Roper, T., Harber, M. A., Jones, G., Pitceathly, R. D. S., & Salama, A. D. (2020) · BMC Nephrology · doi:10.1186/s12882-020-02002-5 · Cited by 5
Liu, Y., Zheng, J., He, Q., Zhang, Y., Wen, P., Wen, P., Ge, J., Yang, Y., Zhang, T., & Wang, R. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001135 · Cited by 5
“Post-transplant diabetes mellitus (PTDM) is a speci fi c disease that affects the transplant population and was previously referred to as new-onset diabetes after transplantation (NODAT) [1 – 3] .”
BackgroundOral Glucose Tolerance Test as a Risk Marker for Developing Post-Transplant Diabetes Mellitus
Rossi, M. R., Mazzali, M., & de Sousa, M. V. (2024) · Transplantation Proceedings · doi:10.1016/j.transproceed.2024.04.021 · Cited by 5
Diabetes Mellitus in Kidney Transplant Recipients: New Horizons in Treatment
Sánchez-Baya, M., Bolufer, M., Vázquez, F., Alonso, N., Massó, E., Paúl, J., Coll-Brito, V., Taco, O., Antón-Pàmpols, P., Gelpi, R., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041048 · Cited by 6
“Classic risk factors include obesity, metabolic syndrome, age, family history of diabetes and being male [5,14,16–18].”
Wei, X., Zhu, D., Feng, C.-C., Chen, G., Mao, X., Wang, Q., Wang, J., & Liu, C. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6706 · Cited by 5
“Cyclosporin A (CsA) is widely used as an immunosuppressor, but clinical study found that after organ transplantation diabetes mellitus associated with the use of immunosuppressants (1,2).”
BackgroundJomphe, V., Nguyen, C. Q. T., Durette, G., Chagnon, M., Nasir, B., Poirier, C. D., Ferraro, P., Lands, L. C., & Mailhot, G. (2019) · Transplantation · doi:10.1097/tp.0000000000002696 · Cited by 5
Miyazaki, R., Miyagi, K., & Yoshida, M. (2020) · Renal Replacement Therapy · doi:10.1186/s41100-020-00303-x · Cited by 5
D’Costa, M. R., Bentall, A., Đenić, A., Schinstock, C. A., Merzkani, M. A., Park, W. D., Ryan, M. S., Alexander, M. P., Smith, B. H., Gandhi, M. J., et al. (2020) · Transplantation · doi:10.1097/tp.0000000000003579 · Cited by 5
“Such studies might include improved control of diabetes, obesity, and hypertension, which has been shown to improve allograft outcomes.(32-34) CNIs have not been shown to improve outcomes in HLA-ID kidney transplantation,(35,36) and CNI-free regimens may also lead to less chronic injury.”
BackgroundGrottenthaler, J. M., Füger, J. K., Mahling, M., Königsrainer, A., Malek, N. P., Birkenfeld, A. L., Nadalin, S., Berg, C. P., Heyne, N., & Guthoff, M. (2021) · Transplant International · doi:10.1111/tri.13967 · Cited by 5
Epstein, F. R., Trammell, J., Liu, C.-M., Denhaerynck, K., Dobbels, F., Russell, C. L., & Geest, S. D. (2022) · Progress in Transplantation · doi:10.1177/15269248221087435 · Cited by 5
Kim, J. G., & Jun, J. H. (2022) · Scientific Reports · doi:10.1038/s41598-022-10994-3 · Cited by 5
Reducing hyperglycaemia post-kidney and liver transplant: a quality improvement initiative
Clemens, K. K., Brahmania, M., Weernink, C., Lotfy, K., Rjoob, H., Berberich, A. J., & Gob, A. (2022) · BMJ Open Quality · doi:10.1136/bmjoq-2021-001796 · Cited by 5
Wang, L., Huang, J., Li, Y., Shi, K., Gao, S., Zhao, W., Zhang, S., Ding, C., & Gao, W. (2023) · Endocrine · doi:10.1007/s12020-023-03374-y · Cited by 5
Rice, C. M., Singh, P., Judd, N. S., Jimenez, E. Y., Blair, C. K., Washburn, A., Calvin, C., Steiber, A. L., Zhu, Y., Argyropoulos, C., et al. (2022) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2022.02.004 · Cited by 5
Long-term Challenges After Solid Organ Transplantation
Legendre, C. M., Viebahn, R., Fehrman‐Ekholm, I., Masnou, N., Berenguer, M., Potena, L., Wennberg, L. M., O’Grady, J., Epailly, É., Diekmann, F., et al. (2018) · Transplantation · doi:10.1097/tp.0000000000002316 · Cited by 5
Iannino, N., Nasri, A., Räkel, A., Ducharme, A., Lachance, K., Racine, N., de Denus, S., Tremblay‐Gravel, M., Fortier, A., & White, M. (2018) · Journal of Transplantation · doi:10.1155/2018/9205083 · Cited by 5
Valentín‐Quiroga, J., Santoveña, A. Z., López‐Collazo, E., & Ferreira, L. M. R. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1601385 · Cited by 5
Hasbal, N. B., Çöpür, S., Peltek, İ. B., Mutlu, A., Atalay, H. Ö., Kesgin, Y. E., Karakaya, A. D., Siriopol, D. C., Koçak, B., & Kanbay, M. (2023) · Clinical Transplantation · doi:10.1111/ctr.15204 · Cited by 4
“4 Metabolic syndrome, a phenomenon with rapidly rising prevalence in adult population, is primarily associated with peripheral insulin resistance along with an increase in serum and tissue levels of certain adipokines and pro-inflammatory cytokines.”
BackgroundGraňák, K., Vnučák, M., Beliančinová, M., Kleinová, P., Blichová, T., Pytliaková, M., & Dedinská, I. (2024) · Medicina · doi:10.3390/medicina60081210 · Cited by 6
“Diabetes mellitus (DM), which occurs after organ transplantation, is a common and serious metabolic complication [1].”
BackgroundZhao, T., Zhao, Y., Zong, A., Tang, Y., Shi, X., & Zhou, Y. (2020) · Journal of International Medical Research · doi:10.1177/0300060520910629 · Cited by 5
“Another major predisposing factor specific to PTDM is immunosuppressive therapy, including glucocorticoid and calcineurin inhibitors (cyclosporine and tacrolimus).(7,11) However, most studies of PTDM have involved kidney and liver transplant recipients in Caucasian populations.”
BackgroundInfluentialRegulation of dual leucine zipper kinase activity through its interaction with calcineurin
Escobar, J. D., Kutschenko, A., Schröder, S., Blume, R., Köster, K.-A., Painer, C., Lemcke, T., Maison, W., & Oetjen, E. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.109953 · Cited by 4
Cyclosporine Treatment in Cats with Presumed Chronic Pancreatitis—A Retrospective Study
Hoeyrup, N., Spillmann, T., & Toresson, L. (2021) · Animals · doi:10.3390/ani11102993 · Cited by 4
“Both in people and in rats, decreased insulin secretion as well as increased insulin resistance are believed to contribute to the hyperglycemia [54,55].”
BackgroundDiabetes Mellitus: Classification and Diagnosis
Marchetti, P., Baronti, W., Boggi, U., & Marselli, L. (2023) · Springer eBooks · doi:10.1007/978-3-031-20999-4_1 · Cited by 5
Lung Transplant for the Critical Care Nurse
Carney, K. C., Bronzell-Wynder, T., & Gronek, K. (2019) · Critical Care Nursing Clinics of North America · doi:10.1016/j.cnc.2019.05.001 · Cited by 5
Sanyal, D., Biswas, M., & Chaudhari, N. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.11.019 · Cited by 4
Mannose-binding lectin genotypes and outcome in end-stage renal disease: a prospective cohort study
Adrian, T., Hornum, M., Eriksson, F., Hansen, J. M., Pilely, K., Garred, P., & Feldt‐Rasmussen, B. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy034 · Cited by 4
Moradi, Z., Toutounchian, S., Akhiani, A., Razaghi, H., Mamdooh, M. A., Bagheri, P., Barkhordar, M., & Salehi, Z. (2026) · BMC Cancer · doi:10.1186/s12885-026-15644-9 · Cited by 3
“Clonal hematopoiesis and chronic immune activation can enhance pro-inflammatory cytokine signaling and macrophage polarization by secreting TNFα and IL-1β, promoting insulin resistance in the liver and peripheral tissues [22, 23].”
Nutrition support considerations in pediatric small bowel transplantation
Nucci, A. M., Crim, K., King, E., Ganoza, A., Remaley, L., & Rudolph, J. A. (2023) · Nutrition in Clinical Practice · doi:10.1002/ncp.11091 · Cited by 3
Du, W., Wang, X., Zhang, D., & Zuo, X. (2024) · Transplant Immunology · doi:10.1016/j.trim.2024.102008 · Cited by 7
Risk Factors and Prediction Score for New-Onset Diabetes Mellitus after Liver Transplantation
Bai, R., An, R. F., Chen, S., Ding, W., Xue, M., Zhao, G., Ma, Q., & Shen, X. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.14204 · Cited by 5
“Studies concluded that whereas HbA1C can be used to diagnose diabetes if elevated ( ≥ 6.5%), it should not be used as a screen for NODALT, particularly in the fi rst year after transplant 27 .”
BackgroundInfluentialSantos, A. H., Leghrouz, M. A., Bueno, E. P., & Andreoni, K. A. (2021) · International Urology and Nephrology · doi:10.1007/s11255-021-02936-1 · Cited by 3
“By including only KTRs with PTDM confirmed through the 12th month of transplant, we avoided the pitfall of including KTRs with transient post-transplant hyperglycemia which occurs in the first few months of KT due to high doses of immunosuppressive drugs [13, 37].”
BackgroundAlireza, H. (2021) · International Journal of Membrane Science and Technology · doi:10.15379/2410-1869.2021.08.02.04 · Cited by 3
van Willigenburg, H., van Domburg, B., Ambagtsheer, G., Brandt, R. M. C., Hesselink, D. A., de Bruin, R. W., & de Winter, B. C. M. (2022) · Bioanalysis · doi:10.4155/bio-2021-0247 · Cited by 3
Bang, J. B., Oh, C., Kim, Y. S., Kim, S. H., Yu, H. C., Kim, C., Ju, M. K., So, B. J., Lee, S. H., Han, S. Y., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1197475 · Cited by 3
Munshi, V. N., Saghafian, S., Cook, C. B., Aradhyula, S. V., & Chakkera, H. A. (2021) · Annals of Transplantation · doi:10.12659/aot.928624 · Cited by 3
“As long-term outcomes were not available in the data, mortality rates or relative mortality risks for each health state were obtained from relevant literature [1,26-31].”
BackgroundStam, S. P., Sokooti, S., Eisenga, M. F., van der Veen, A., Neto, A. W. G., van Dijk, P. R., van Zanden, J. J., Vos, M. J., Kema, I. P., van Beek, A. P., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0237 · Cited by 3
“Subsequently, transplantationspecific risk factors, such as the use of immunosuppressive drugs, and traditional risk factors including BMI were discovered as important determinants (7,8).”
BackgroundStrategies to Improve Immune Suppression Post-Liver Transplantation: A Review
Mohamed, I. B., Aloor, F. Z., & Jalal, P. K. (2021) · Transplantology · doi:10.3390/transplantology2040042 · Cited by 7
Medical Complications After Kidney Transplantation: Early
Brahmbhatt, Y. G. (2018) · Springer eBooks · doi:10.1007/978-3-319-19617-6_14 · Cited by 3
Vinson, A. J., Thanamayooran, A., KIBERD, B. A., West, K. A., Siddiqi, F. S., Gunaratnam, L., & Tennankore, K. (2022) · Kidney360 · doi:10.34067/kid.0003742022 · Cited by 3
“Given that maintenance immunosuppression at our center consists of tacrolimus, prednisone, and mycophenolic acid in nearly all patients, individual effects of either tacrolimus or prednisone maintenance therapy could not be determined (34).”
BackgroundOutcome of liver transplantation in elderly patients: an Italian multicenter case–control study
Melandro, F., Lai, Q., Ghinolfi, D., Manzia, T. M., Spoletini, G., Rossi, M., Agnes, S., Tisone, G., & SIMONE, P. D. (2023) · Updates in Surgery · doi:10.1007/s13304-023-01448-0 · Cited by 3
Post-Transplant Diabetes Mellitus
Bhattarai, M., & Bhayana, S. (2022) · Springer eBooks · doi:10.1007/978-3-031-13569-9_61 · Cited by 3
Hu, L., Zhang, X., Zhang, W., Jin, S., Zhao, J., Zheng, J., Song, W., & Shen, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1539645 · Cited by 2
From bench to bed: deep insights the tacrolimus-induced diabetes and gut microbiota dysbiosis
Han, Y., Bian, Z., Zhao, J., Xiao, H., Wang, H., Gao, F., Shi, W., Liu, J., Xu, J., & Xu, C. D. (2025) · European journal of medical research · doi:10.1186/s40001-025-03000-9 · Cited by 4
“Diabetes and insulin resistance (IR) represent significant clinical challenges in LT, affecting graft function and patient outcomes [7].”
Metadata
- Authors
- Shivaswamy, V., Boerner, B., & Larsen, J.
- Affiliations
- VA Nebraska Western Iowa Health Care System (US)
- University of Nebraska Medical Center (US)
- Corresponding author
- Larsen, Jennifer
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2015-12-09
- Volume
- 37
- Issue
- 1
- Pages
- 37-61
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC4740345
- OpenAlex
- W2190934800
- Cited by
- 328
- References
- 230
- Citations by year
- 2026: 30 · 2025: 36 · 2024: 35 · 2023: 31 · 2022: 32 · 2021: 44 · 2020: 51 · 2019: 29 · 2018: 30 · 2017: 5 · 2016: 4
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrine Reviews (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- Office of Research and Development
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- post-transplant diabetes mellitus, solid organ transplantation, immunosuppression, corticosteroids, impaired glucose tolerance, diabetes screening, HbA1c, type 2 diabetes risk factors, drug-drug interactions, hypoglycemia, graft survival, mortality, infection risk, diabetes treatment
- MeSH terms
- Adrenal Cortex Hormones, Animals, Combined Modality Therapy, Diabetes Mellitus, Graft Rejection, Graft Survival, Humans, Immunosuppressive Agents, Postoperative Complications, Risk Factors, Stress, Physiological, Organ Transplantation, Cost of Illness, Practice Guidelines as Topic, Evidence-Based Medicine, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.